Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
284 hedge funds and large institutions have $11.5B invested in Mirati Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 81 funds opening new positions, 101 increasing their positions, 81 reducing their positions, and 21 closing their positions.
286% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 21
110% more call options, than puts
Call options by funds: $232M | Put options by funds: $110M
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
44% more capital invested
Capital invested by funds: $8B → $11.5B (+$3.52B)
26% more funds holding
Funds holding: 225 → 284 (+59)
25% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 81
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$188M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$149M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$133M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$87.7M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$78.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$203M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$157M |
| 3 |
O
OrbiMed
New York
|
-$37.1M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$37.1M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$36.3M |
MRTX Hedge Fund Activity: Q4 2020 in Review
284 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2020, worth a combined $11.5B — up 44% from $8B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new MRTX positions and 21 closed out — a net gain of 60 holders — while 101 added to existing stakes and 81 trimmed.
The largest buyer was BlackRock, adding an estimated $188M. The largest seller was Sands Capital Management, cutting an estimated $203M.
- 284 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2020, up from 225 in Q3 2020.
- Funds reported $11.5B of Mirati Therapeutics, Inc. Common Stock stock for Q4 2020, up 44% quarter-over-quarter.
- 81 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2020 and 21 closed out, a net change of +60 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2020 was BlackRock, an estimated $188M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2020 was Sands Capital Management, an estimated $203M sold.
Based on aggregated 13F filings for Q4 2020.